Should you buy Illumina (ILMN)?
Updated
Four consecutive earnings beats averaging nearly 13% above consensus, best-in-class margins, a 34% return on equity, and a near-perfect financial health score make the quality case compelling — but revenue heavily concentrated in a single technology segment, reliance on single-source suppliers, and a forward earnings multiple above 28 times leave the risk/reward thin at the current price with the stock already past its analyst-derived target.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Net margins of 19%, a return on equity of 34%, and a financial health score of 8 out of 9 reflect a business with strong profitability, sound balance sheet management, and operating efficiency that ranks best-in-class relative to peers. Quality | Return on equity remains above 25% and net margins hold above 15% over the next four reported quarters, sustaining the quality premium. | →Stable |
| CounterThe combined growth and profitability score (Rule of 40 at 24) falls below the 40-point threshold typically associated with software businesses able to sustain premium multiples, suggesting the quality metrics may not be sufficient to justify the current valuation without re-acceleration in revenue growth. | ||
The company has beaten consensus earnings estimates in each of the last four consecutive quarters, with average outperformance of nearly 13% above expectations — a consistent pattern of delivering results above what analysts anticipated, most recently in April 2026. Catalyst | EPS continues to exceed consensus estimates in each of the next two quarters, sustaining the track record of consistent outperformance. | →Stable |
| CounterThe margin of outperformance has narrowed from over 17% in the oldest of the four quarters to 9% in the most recent, which may indicate that estimates are catching up to the company's actual trajectory — reducing the runway for further positive surprises. | ||
Sequencing-related revenue represents 92% of total revenue, creating material concentration risk — a slowdown, competitive disruption, or technology transition in that single segment could materially impair the overall business even if other areas perform well. Bear case | Revenue from segments outside the dominant product line grows to represent at least 15% of total revenue over 12 months, meaningfully reducing the concentration. | →Stable |
| CounterHigh concentration in one category can also reflect genuine market leadership in that category; if the underlying sequencing market continues to grow, concentration in the leading product may be a strength rather than a vulnerability. | ||
Net margins of 19%, a return on equity of 34%, and a financial health score of 8 out of 9 reflect a business with strong profitability, sound balance sheet management, and operating efficiency that ranks best-in-class relative to peers.
→Stable- Expectation
- Return on equity remains above 25% and net margins hold above 15% over the next four reported quarters, sustaining the quality premium.
CounterThe combined growth and profitability score (Rule of 40 at 24) falls below the 40-point threshold typically associated with software businesses able to sustain premium multiples, suggesting the quality metrics may not be sufficient to justify the current valuation without re-acceleration in revenue growth.
The company has beaten consensus earnings estimates in each of the last four consecutive quarters, with average outperformance of nearly 13% above expectations — a consistent pattern of delivering results above what analysts anticipated, most recently in April 2026.
→Stable- Expectation
- EPS continues to exceed consensus estimates in each of the next two quarters, sustaining the track record of consistent outperformance.
CounterThe margin of outperformance has narrowed from over 17% in the oldest of the four quarters to 9% in the most recent, which may indicate that estimates are catching up to the company's actual trajectory — reducing the runway for further positive surprises.
Sequencing-related revenue represents 92% of total revenue, creating material concentration risk — a slowdown, competitive disruption, or technology transition in that single segment could materially impair the overall business even if other areas perform well.
→Stable- Expectation
- Revenue from segments outside the dominant product line grows to represent at least 15% of total revenue over 12 months, meaningfully reducing the concentration.
CounterHigh concentration in one category can also reflect genuine market leadership in that category; if the underlying sequencing market continues to grow, concentration in the leading product may be a strength rather than a vulnerability.
▸ Show 1 more pillar▾ Show fewer
A forward price-to-earnings ratio of 28 times and a price-to-earnings-to-growth ratio of 2.93 place the stock at a premium that leaves little room for estimate disappointment — the current price has already moved past the analyst-derived target, and the risk/reward geometry does not support the current entry.
→Stable- Expectation
- The forward multiple compresses below 20 times as earnings growth accelerates to close the gap between price and intrinsic value, restoring a more balanced risk/reward.
CounterPremium multiples can be sustained or expanded when earnings consistently exceed expectations — four straight beats suggest the company may be under-promising and over-delivering, which can justify a persistent multiple premium above what the trailing growth rate alone would imply.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has beaten consensus earnings estimates in each of the last four consecutive quarters, with average outperformance of nearly 13% above expectations — a consistent pattern of delivering results above what analysts anticipated, most recently in April 2026.
Trip ifEPS falls below consensus in 2 consecutive quarters, breaking the four-quarter beat streak.
- P2Net margins of 19%, a return on equity of 34%, and a financial health score of 8 out of 9 reflect a business with strong profitability, sound balance sheet management, and operating efficiency that ranks best-in-class relative to peers.
Trip ifReturn on equity falls below 15% for 2 consecutive reported quarters, a material decline from the current 34% level.
- P3Sequencing-related revenue represents 92% of total revenue, creating material concentration risk — a slowdown, competitive disruption, or technology transition in that single segment could materially impair the overall business even if other areas perform well.
Trip ifRevenue from non-sequencing segments grows to represent more than 20% of total revenue, reducing sequencing concentration below 80%.
- P4A forward price-to-earnings ratio of 28 times and a price-to-earnings-to-growth ratio of 2.93 place the stock at a premium that leaves little room for estimate disappointment — the current price has already moved past the analyst-derived target, and the risk/reward geometry does not support the current entry.
Trip ifForward price-to-earnings ratio compresses below 20x, indicating the valuation premium has meaningfully resolved.
How the engine reached this verdict
TrendMatrix's engine output for Illumina, Inc. (ILMN) is HOLD_IF_HOLDING with medium conviction, score 4.8/10 at $179.65. The F-path SELL output reflects an overall score of 4.8 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -1.71 is supplementary context, not the trigger.
On the bull side: Strong earnings beat streak (4/4); Positive news sentiment (+0.67); High-quality business. On the bear side: Concentration risk — Product: sequencing revenue (92.0%); Concentration risk — Supplier: single-source suppliers; Analyst target reached - limited upside remaining. Active engine warnings: V8: Target reached (-25.7% upside), L3:NEWS_MOD=+2: SELL_IF_HOLDING → HOLD_IF_HOLDING, V9 Gate Failed: ASYMMETRY:-1.7=NEGATIVE.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $168.77 for existing positions. Asymmetric R:R is -0.19, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ILMN — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸Positive news sentiment (+0.67)
- ▸High-quality business
Bear case
- ▸Concentration risk — Product: sequencing revenue (92.0%)
- ▸Concentration risk — Supplier: single-source suppliers
- ▸Analyst target reached - limited upside remaining